Press Releases

Date Title  
Toggle Summary Allergen Research Corporation Expands Management with New VP Functions
Mary Rozenman, PhD, Joins ARC as Senior Vice President, Corporate and Commercial Development, and Mike Holfinger, PhD, Joins as Vice President, Manufacturing SAN MATEO, Calif., April 8, 2015 – Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing
Toggle Summary Allergen Research Corporation Completes $80 Million Series B Financing to Advance Drug Development Portfolio for Food Allergy
Jim Tananbaum, MD, and Stacey Seltzer Join ARC Board of Directors SAN MATEO, Calif., March 12, 2015 – Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced the completion of an $80 million
Toggle Summary Allergen Research Corporation Initiates Phase 2b Clinical Trial for Peanut Allergy Oral Immunotherapy (OIT)
Study Marks Progress toward Making Gains from OIT Research Clinically Available for Food Allergy Treatment SAN MATEO, Calif., February 27, 2014— Allergen Research Corporation (ARC), a privately held company developing desensitization treatment protocols and products for food allergies, today
Toggle Summary Allergen Research Corporation Announces $17 Million Series A Financing
Funds Will Support Phase 2b Clinical Trial for Peanut Allergy Oral Immunotherapy SAN MATEO, Calif., November 21, 2013— Allergen Research Corporation (ARC), a privately held company developing desensitization treatment protocols and products for food allergies, today announced the successful